TY - JOUR T1 - Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms JF - In Vivo JO - In Vivo SP - 2425 LP - 2432 DO - 10.21873/invivo.12520 VL - 35 IS - 4 AU - YOSUKE HORITA AU - KYOICHI KAIRA AU - TOMONORI KAWASAKI AU - YOSHIAKI MIHARA AU - SHINICHI SAKURAMOTO AU - SHIGEKI YAMAGUCHI AU - KOJUN OKAMOTO AU - SHOMEI RYOZAWA AU - YOSHIKATSU KANAI AU - MASANORI YASUDA AU - TETSUYA HAMAGUCHI Y1 - 2021/07/01 UR - http://iv.iiarjournals.org/content/35/4/2425.abstract N2 - Background/Aim: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. Patients and Methods: Tissues from 126 patients with GEP-NENs were collected between August 2007 and August 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. Results: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). Conclusion: No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident. ER -